February 24, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG Oncology names Dr. Charles Geyer as Associate Group Chair

The NRG Oncology Group Chairs have created the position of Associate Group Chair and have selected Charles E. Geyer, Jr., MD, to fill the position effective immediately. Read more

TERMINATION

GYNECOLOGIC

GOG-0274/ANZGOG 0902-The OUTBACK Trial: Terminated effective July 19, 2024; version date: September 21, 2022 (posted on CTSU)

CLOSURES

CANCER PREVENTION & CONTROL

NRG-CC013: Temporarily Closed to accrual, study memo dated February 21, 2025 (posted on CTSU)

GYNECOLOGIC

NRG-CC008/SOROCk: 3 slots remaining for the 42-50 age block of the BSO arm. Once these slots are filled, accrual will be temporarily held to allow the 42-50 age block of the BLS arm to enroll the same number of patients. This age blocking is specified in the protocol to ensure equal distributions of patients because this is a non-randomized study. Please see protocol Section 14.5 for a description of the age blocking. (posted on CTSU)

AMENDMENTS

SYMPTOM MANAGEMENT

NRG-CC011: Amendment 1; version date: November 15, 2024 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN003: The Spanish-translated consent form for Amendment 7 and CIRB approval of the form are available on CTSU.

4. BREAST

NRG-BR008/HERO: Study webinars are being held via Microsoft Teams on March 24th at 3pm ET and March 26th at 11am ET. Please see the memorandum, dated February 24, 2025, (posted on CTSU) for details and how to register for one of the sessions. Please note: Google Chrome is the preferred browser to register for the webinars.

5. CANCER PREVENTION & CONTROL

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

6. GYNECOLOGIC

NRG-GY026: Please note, the post-chemo cfDNA Whole Blood (WB03) should only be collected if the Pre-Treatment cfDNA Whole Blood (WB01) was collected.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

NRG-HN014

The following documents are posted on the CTSU website. The documents provide logistics for sites unable to submit biopsy blocks.

• Biospecimen Logistics Study Memorandum (version date February 20, 2025)
• Updated Biospecimen Collection and Submission Manual (version date February 20, 2025)

8. LUNG

S1914: A memorandum has been posted on CTSU regarding termination of QOL instructing sites to discontinue administration as of February 1, 2025. All delinquent QOL data up until this date is to be entered into Rave for S1914-E-01. Please review all cases at your site for completion. 

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC003, NRG-CC005, NRG-CC011, NRG-CC013, NRG-HN001, NRG-HN002, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for March 12, 2025.

Investigator’s Brochure (IB*) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG Oncology names Dr. Charles Geyer as Associate Group Chair

The NRG Oncology Group Chairs have created the position of Associate Group Chair and have selected Charles E. Geyer, Jr., MD, to fill the position effective immediately. Read more

2. NRG Oncology Currents eNewsletter

The February issue of the NRG Currents eNewsletter is now available. See this month's protocols in development, FORTE Study updates, Advocate Angle column, NRG Winter Meeting recap, and more! Read more

3. Important Message from the NCTN Group Chairs

A message emphasizing the importance of research funding and inviting our members to engage in informing legislators about the critical importance of NIH and NCI’s mission. Read more

4. NRG Group Chairs Message on Current Concerns

A statement was released from the NRG Oncology Group Chairs on February 14^th, addressing current concerns and highlighting the value of research. Read more

5. NRG Oncology GYN Cancer Committee is Requesting Proposals

Submit your proposals in advance of the April 11, 2025 Interim Meeting. Read more

REMINDER: Any manuscript or abstract resulting from research conducted under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association.

Please reach out to NRG-Publications@NRGOncology.org as a first step to ensure all requirements are met.

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract. 

PUBLISHED ARTICLES 

Pugh SL, Lee C, Dunn BK, Dignam JJ. The importance of patient-centered research in oncology clinical trials: motivation for the Monograph series. J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):1-2. doi: 10.1093/jncimonographs/lgae052. PMID: 39989042. Read more 

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 25-30, 2025; Chicago, IL

American Association for Thoracic Surgery (AATS); May 2-5, 2025; Seattle, WA

American Brachytherapy Society (ABS); Jun 18-21, 2025; Nashville, TN

American College of Radiology (ACR); May 3-7, 2025; Washington, DC

American Head & Neck Society (AHNS); May 14-15, 2025; New Orleans, LA

American Radium Society (ARS) Annual Meeting; Apr 3-6, 2025; Seattle, WA

American Surgical Association (ASA); Apr 24-26, 2025; San Diego, CA

American Society of Breast Surgeons (ASBrS); Apr 30-May 4, 2025; Las Vegas, NV

American Society of Colon and Rectal Surgeons (ASCRS); May 11-14, 2025; San Diego, CA

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB

Miami Breast Cancer Conference; Mar 6-9, 2025; Miami, FL

Society for Clinical Trials (SCT); May 18-21, 2025; Vancouver, BC

Society for Gynecologic Oncology (SGO); Mar 14-17, 2025; Seattle, WA

Society of Surgical Oncology (SSO) Annual Meeting; Mar 27-29, 2025; Tampa, FL

St. Gallen Breast Cancer Conference; Mar 12-15, 2025; Vienna Austria 

UPCOMING ABSTRACT SUBMISSION DEADLINES

AACR Conference On the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD; Due to publications committee Jun 10, 2025; Submission deadline Jun 24, 2025, 1:00 pm ET

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL; LBA Mar 5, 2025 (placeholder required)

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA; Submission deadline Feb 25, 2025, 11:59 pm PT; LBA Jul 10, 2025, 11:59 pm PT

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; Due to publications committee Apr 25, 2025; Submission deadline May 13, 2025, 21:00 CET; LBA Sep 9, 2025, 21:00 CET (placeholder required)

ESMO Breast Cancer; May 14-16, 2025; Munich, Germany; LBA Apr 15, 2025, 21:00 CET (placeholder required)

ESMO Gastrointestinal Cancers; Jul 2-5, 2025; Barcelona, Spain; Due to publications committee Mar 25, 2025; Submission deadline Apr 8, 2025, 21:00 CET; LBA Jun 5, 2025, 21:00 CET (placeholder required)

ESMO Gynaecological Cancers; Jun 19-21, 2025; Vienna, Austria; Due to publications committee Mar 18, 2025; Submission deadline Apr 1, 2025, 21:00 CET

European Society for Radiotherapy and Oncology (ESTRO); May 2-6, 2025; Vienna, Austria; LBA Mar 19, 2025

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI; Due to publications committee Mar 25, 2025; Submission deadline Apr 7, 2025



Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL; Due to publications committee Apr 23, 2025; Submission deadline May 7, 2025, Noon CT